04:11 AM EDT, 10/24/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Friday it has transferred Nanoray-312 sponsorship to Johnson & Johnson ( JNJ ) , including the transfer of operational control of the phase 3 head and neck cancer study.

The company expects that Nanoray-312, which started in Q3 2024, interim data will be analyzed and reported in H1 2027, Nanobiotix ( NBTX ) said.

Johnson & Johnson ( JNJ ) will provide future updates regarding Nanoray-312 and other JNJ-1900-related sponsored trials, while Nanobiotix ( NBTX ) will continue to offer JNJ-1900 clinical development updates, according to the company.

JNJ-1900 oncology product is being evaluated throughout multiple solid tumor indications as a single agent or combination therapy.